Linsidomine
Chemical compound
- C01DX18 (WHO)
- 5-imino-3-morpholin-4-yl-5H-1,2,3-oxadiazol-3-ium-2-ide
- 33876-97-0
Y
16142-27-1 (hydrochloride)
- 5219
- 10561427
- 5O5U71P6VQ
- D07161 Y
- DTXSID501026026
- Interactive image
- C1COCCN1[N+]2=NOC(=C2)[NH-]
InChI
- InChI=1S/C6H10N4O2/c7-6-5-10(8-12-6)9-1-3-11-4-2-9/h5,7H,1-4H2
- Key:FKDHHVKWGRFRTG-UHFFFAOYSA-N
Linsidomine (3-morpholinosydnonimine or SIN-1[1]) is a vasodilator. It is a metabolite of the antianginal drug molsidomine and acts by releasing NO from the endothelial cells nonenzymatically. It also hyperpolarizes the cell membrane through influencing the sodium-potassium pump and thereby rendering it less responsive to adrenergic stimulation. Linsidomine injection at a dose of 1 mg produces usable erection[2] in about 70% of patients and full erection in up to 50% of patients. Linsidomine does not appear to be associated with priapism.[citation needed]
Linsidomine is neurotoxic and promotes oxidative stress on neurons.[3] Linsidomine is a peroxynitrite-generating compound involved in the pathogenesis of neurodegenerative diseases.[4]
References
- ^ Wen TC, Rogido MR, Moore JE, Genetta T, Peng H, Sola A (October 2005). "Cardiotrophin-1 protects cortical neuronal cells against free radical-induced injuries in vitro". Neuroscience Letters. 387 (1): 38–42. doi:10.1016/j.neulet.2005.07.018. PMID 16084018.
- ^ Lemaire A, Buvat J (June 1998). "[Erectile response to intracavernous injection of linsidomine in 38 impotent patients. Comparison with prostaglandin E1]". Progres en Urologie. 8 (3): 388–91. PMID 9689672.
- ^ Wallace DR, Dodson S, Nath A, Booze RM (January 2006). "Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function". Synapse. 59 (1): 51–60. doi:10.1002/syn.20214. PMID 16237680.
- ^ Jang JH, Aruoma OI, Jen LS, Chung HY, Surh YJ (February 2004). "Ergothioneine rescues PC12 cells from beta-amyloid-induced apoptotic death". Free Radical Biology & Medicine. 36 (3): 288–99. doi:10.1016/j.freeradbiomed.2003.11.005. PMID 15036348.
- v
- t
- e
Vasodilators used in cardiac diseases (C01D)
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
